ImmunoGen Inc. (IMGN) announced Saturday that it presented results from an ongoing Phase 1 trial of mirvetuximab soravtansine at the ASCO meeting. An objective response rate of 53% was observed in patients with folate-receptor alpha (FRa)-positive platinum-resistant ovarian cancer. The company is preparing to initiate a Phase 2 trial in late 2015.
ImmunoGen gapped open sharply higher Monday morning and has spiked to the upside in early trade. The stock is now up 4.34 at $13.32 on above average volume. ImmunoGen has surged to over an 11-month high.
For comments and feedback contact: editorial@rttnews.com
Business News